Compare Iris Energy Limited (IREN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iris Energy Limited vs Merck & Co., Inc. — how do they compare? Iris Energy Limited trades at $34.9 (market cap $14.07B), while Merck & Co., Inc. trades at $146.22 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 25× Iris Energy Limited's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and Merck & Co., Inc. for 98 Days on average.
| IREN | MRK | |
|---|---|---|
Market Cap | $14.07B | $351.28B |
Volume | 54,492,460 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $76.41 | $156.43 |
52-Week Low | $29.31 | $82.49 |
Typical Hold Time | 28 Days | 98 Days |
Enterprise Value | $16.02B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IREN stock trades at $35.05, down 9.41% in 24 hours amid a bearish technical signal. The company is executing a pivot from Bitcoin mining to AI cloud services, with a $9.7 billion Microsoft deal, but faces ballooning losses and negative net margins. Analyst consensus remains bullish with an $81 price target, yet recent earnings misses and high valuations (P/E 51.42) highlight execution risks.
Outlook: Long-term growth potential from AI infrastructure demand is significant, but near-term profitability challenges and capital intensity pose risks. Investors should weigh strong analyst support against weak earnings trends and high cash burn from aggressive expansion plans.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
